This Everyday AI podcast episode interviews Lina Nilsson, SVP and Head of Platform and Product at Recursion Pharmaceuticals, about the application of generative AI in drug discovery. The discussion covers Recursion's use of AI and CRISPR technology to accelerate drug development, reducing the time and cost associated with bringing new treatments to market. Nilsson highlights how AI is streamlining processes like literature review (reducing time by 60%) and enabling the analysis of vast datasets to identify novel drug candidates. A key takeaway is the shift towards "world models" in AI, which aim to understand broad domains like human health, rather than solving single problems. The potential impact is faster, cheaper drug development and the possibility of preventative treatments to improve human health and longevity.
